Acadian Asset Management LLC A Tyr Pharma Inc Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.42 - $2.02 $35,079 - $49,902	24,704 Added 119.56%	45,366 $87,000
Q4 2023 Feb 13, 2024	BUY	$1.11 - $1.51 $22,934 - $31,199	20,662 New	20,662 $29,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $2.49 $53,366 - $65,783	26,419 New	26,419 $57,000
Q2 2022 Aug 09, 2022	BUY	$2.63 - $5.61 $52,502 - $111,992	19,963 New	19,963 $57,000
Q3 2021 Nov 12, 2021	SELL	$4.22 - $12.48 $180,295 - $533,195	-42,724 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.62 - $4.88 $217,102 - $292,668	-59,973 Reduced 58.4%	42,724 $208,000
Q1 2021 May 11, 2021	BUY	$3.53 - $8.06 $69,346 - $158,338	19,645 Added 23.65%	102,697 $457,000
Q3 2020 Nov 09, 2020	BUY	$3.23 - $5.39 $48,734 - $81,324	15,088 Added 22.2%	83,052 $269,000
Q2 2020 Aug 12, 2020	BUY	$2.55 - $4.58 $173,308 - $311,275	67,964 New	67,964 $302,000
Q4 2019 Feb 06, 2020	SELL	$3.03 - $4.83 $92,645 - $147,682	-30,576 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$2.8 - $5.46 $85,612 - $166,944	30,576 New	30,576 $107,000

37.1M

30.2K

3.1K

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $53.2M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.